Back to Clinical Trials
N/ARecruiting

Intermittent Hypoxia in Persons With Multiple Sclerosis

Sponsored by Shirley Ryan AbilityLab

About this study

This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.

Recent research has shown that AIH, characterized by brief episodes of reduced oxygen levels in the inspired air, has the potential to induce neural adaptations. These adaptations are suspected to influence several aspects of neuroplasticity, including the modulation of neurotransmitters and neurotrophic factors. Persons with MS typically exhibit greater cortical activation to achieve a given motor task compared to healthy controls, suggesting compensatory activations in motor cortices and the recruitment of additional non-motor regions for successful motor control. Therefore, interventions that promote adaptive neuroplasticity in motor control systems may induce a reduction in fMRI activation during motor tasks as well as an increase in functional connectivity between somatomotor cortices…

Where this study is enrolling

Who can participate

Inclusion criteria

  • ✓Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS)
  • ✓Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5
  • ✓Motor Functional System Scale (FSS) between 2-4
  • ✓Relapse free for at least 1 year
  • ✓Age ≥ 18 years and ≤ 75 years
  • ✓Safe to be scanned based on MRI questionnaire
  • ✓Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening

Exclusion criteria

  • ✕Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan
  • ✕Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55)
  • ✕History of epilepsy
  • ✕Chronic obstructive pulmonary disease
  • ✕Uncontrolled Sleep apnea
  • ✕Pregnancy

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.